RECOVERY Trial: Randomised Evaluation of COVID-19 Therapy
Principal Investigator: Prof. Anil Hormis Sponsor: University of Oxford This international clinical trial aims to identify treatments that may be beneficial for people hospitalised with suspected or confirmed COVID-19. |
REMAP-CAP: Randomised, Embedded, Multifactorial, Adaptive Platform trial for Community-Acquired Pneumonia
Principal Investigator: Prof. Anil Hormis Sponsor: University Medical Centre Utrecht / Intensive Care National Audit & Research Centre (ICNARC) The broad objective of this REMAP is, over time, to determine and continuously update the optimal set of treatments for community-acquired pneumonia. This study will use a study design known as a REMAP, a Randomised, Embedded, Multifactorial, Adaptive Platform trial. |
COV-COMPARE Immunogenicity of vaccine VLA2001 compared to AZD1222
Principal Investigator: Prof. Anil Hormis Sponsor: Valneva Austria GmbH This is a multicentre, randomised, observer blind, active-controlled, superiority study to compare the immunogenicity of VLA2001 to AZD1222 in terms of GMT. |